作者
Claudia C.S. Chini,Thais Peclat,Gina M. Warner,Sonu Kashyap,Jair M. Espindola-Netto,Guilherme C. de Oliveira,Lilian Sales Gomez,Kelly A. Hogan,Mariana G. Tarragó,Amrutesh S. Puranik,Guillermo Agorrody,Katie L. Thompson,Kevin Dang,Starlynn Clarke,Bennett G. Childs,Karina S. Kanamori,Micaela A. Witte,Paola Vidal,Anna L. Kirkland,Marco De Cecco,Karthikeyani Chellappa,Melanie R. McReynolds,Connor S.R. Jankowski,Tamar Tchkonia,James L. Kirkland,John M. Sedivy,Jan M. van Deursen,Darren J. Baker,Wim van Schooten,Joshua D. Rabinowitz,Joseph A. Baur,Eduardo N. Chini
摘要
Decreased NAD+ levels have been shown to contribute to metabolic dysfunction during aging. NAD+ decline can be partially prevented by knockout of the enzyme CD38. However, it is not known how CD38 is regulated during aging, and how its ecto-enzymatic activity impacts NAD+ homeostasis. Here we show that an increase in CD38 in white adipose tissue (WAT) and the liver during aging is mediated by accumulation of CD38+ immune cells. Inflammation increases CD38 and decreases NAD+. In addition, senescent cells and their secreted signals promote accumulation of CD38+ cells in WAT, and ablation of senescent cells or their secretory phenotype decreases CD38, partially reversing NAD+ decline. Finally, blocking the ecto-enzymatic activity of CD38 can increase NAD+ through a nicotinamide mononucleotide (NMN)-dependent process. Our findings demonstrate that senescence-induced inflammation promotes accumulation of CD38 in immune cells that, through its ecto-enzymatic activity, decreases levels of NMN and NAD+. Chini et al. demonstrate that CD38+ expression in immune cells increases during aging, owing to the senescence-associated secretory phenotype of senescent cells, and the ecto-enzymatic activity of CD38+ affects intracellular NAD+ levels in vivo by hydrolyzing the NAD+ intermediate nicotinamide mononucleotide extracellularly.